MedTrace Logo

Management of Prostatodynia in Younger Patients With Non-ablative Erbium:YAG Intraurethral Laser

NCT04446598 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-06-25

No results posted yet for this study

Summary

This prospective study aimed to compare the clinical outcomes between the use of the erbium: YAG (Er:YAG) laser, intraurethrally administered in long non-ablative SMOOTH™ train of pulses applied at the level of the male prostatic urethra, to the use of the pharmacological treatment of oral tadalafil for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The results show that both treatments are effective in alleviating symptoms of CP/CPPS. The non-ablative Er:YAG SMOOTHTM laser seems to be a promising treatment for this widely spread condition. More studies are needed to confirm its safety and efficacy.

Conditions

  • Chronic Prostatitis With Chronic Pelvic Pain Syndrome
  • Prostatodynia

Interventions

DEVICE

non-ablative SMOOTH mode Erbium YAG laser

Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode

DRUG

Tadalafil 5mg

oral tadalafil 5 mg was administered daily over a period of two months

Sponsors & Collaborators

  • Adrian Gaspar

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2018-11-30
Completion
2018-12-31

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04446598 on ClinicalTrials.gov